Valneva (VLA) Q3 2025 earnings summary

Executive summary

• Total revenues for the first nine months of 2025 reached €127.0 million, up 8.9% year-over-year, driven by proprietary vaccine sales despite geopolitical, currency, and third-party sales headwinds.

• Net loss was €65.2 million, compared to a net profit of €24.7 million in the prior year, which included a one-time €90.8 million gain from a Priority Review Voucher sale.

• Operating cash burn was significantly reduced to €28.4 million from €76.7 million year-over-year.

• Financial flexibility improved through successful debt refinancing, extending maturity to Q4 2030, and proceeds from ATM transactions.

• Key business highlights included responses to disease outbreaks, new contracts, and regulatory progress for multiple vaccines.

Financial highlights

• Product sales were €119.4 million, up 6.2% year-over-year; IXIAROⓇ/JESPECTⓇ sales grew 12.5% to €74.3 million, IXCHIQⓇ sales rose 330% to €7.6 million.

• DUKORALⓇ sales decreased to €21.5 million, impacted by currency and distributor transition in Germany.

• Gross margin on commercial products (excluding IXCHIQⓇ) improved to 57.2% from 48.6% year-over-year.

• Operating loss was €53.9 million versus a €34.2 million profit last year, which included a €90.8 million one-time gain.

• Adjusted EBITDA was negative €37.7 million, compared to positive €48.6 million last year.

Outlook and guidance

• Full-year 2025 product sales guidance confirmed at €155–€170 million; total revenues expected at €165–€180 million.

• R&D expenses projected at €80–€90 million, partially offset by grants and tax credits.

• Commercial business expected to remain cash-flow positive, with a focus on maintaining sufficient runway to key milestones.

• Sustainable profitability anticipated post-approval and commercialization of the Lyme disease vaccine, with potential from 2027.